Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome

Gattini, Daniela; Belza, Christina; Kraus, Raphael; Avitzur, Yaron; Ungar, Wendy J.; Wales, Paul W.

doi:10.1016/j.clnu.2023.10.001

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El principal impedimento para su uso genera-lizado es su alto costo, el que se estima en $329.960 dólares canadienses por paciente por año. En un estudio sobre costo-efectividad se concluyó que aunque teduglutide no resultó ser rentable para disminuir el soporte de NP en niños con SIC, iniciar su uso una vez que la adaptación intestinal natural se reduce y ajustar su costo mensual para reflejar el costo por volumen según la dosificación basada en el peso hizo que la intervención fuera altamente rentable en comparación con el estándar de atención 7 . Es fundamental considerar la implementación de esta terapia en Chile para ampliar las alternativas terapéuticas de los niños con SIC.…”

unclassified

Desafíos en el manejo de la Insuficiencia Intestinal

Alberti Reus

2024

Andes pediatr

View full text Add to dashboard Cite

unclassified

Desafíos en el manejo de la Insuficiencia Intestinal

Alberti Reus

2024

Andes pediatr

View full text Add to dashboard Cite

Intestinal adaptation and rehabilitation in adults with short bowel syndrome

Pironi

2024

Current Opinion in Clinical Nutrition &Amp; Metabolic Care

View full text Add to dashboard Cite

Purpose of review Over the past decade, trophic gastrointestinal hormonal factors have been included in the intestinal rehabilitation programs for short bowel syndrome (SBS). Up today the only trophic factor approved for clinical practice is the glucagon-like peptide-2 (GLP-2) analogue, teduglutide. A literature review on the last 2-year data on GLP-2 analogues for the treatment of SBS in adults has been performed. Recent findings Several reports on real-world data on the efficacy and safety of teduglutide treatment for SBS, some case-reports on the use of teduglutide in non-SBS conditions as well as phase 2 trials on new GL-2 analogues on patients with SBS have been retrieved, Summary Real-world data confirmed the teduglutide efficacy not only in weaning off IVS in accurately selected patients but also increased the alert on the risk of development of gastrointestinal polyps related to the drug; the impact of the therapy on patients’ QoL deserves further studies and the cost-utility of the treatment is still uncertain. Some case reports highlighted the potential benefit of treatment with teduglutide in non-SBS gastrointestinal diseases, such as graft-versus-host disease, primary amyloidosis and refractory microscopic colitis. Phase 2 RCTs on safety and efficacy of two new long-acting GLP-2 analogues, glepaglutide and apraglutide, were published, and phase 3 RCTs have been completed.

show abstract

Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome

Cited by 2 publications

References 53 publications

Desafíos en el manejo de la Insuficiencia Intestinal

Desafíos en el manejo de la Insuficiencia Intestinal

Intestinal adaptation and rehabilitation in adults with short bowel syndrome

Contact Info

Product

Resources

About